Asset sale Completed
LEO Pharma acquisition of global rights for MT-7117 (dersimelagon)
US$435m consideration
Announced Aug 2026
Advisers
LEO Pharma
Acquirer
- Legal adviser
- Target
- Worldwide rights to dersimelagon
- Acquirer
- LEO Pharma
- Seller
- Tanabe Pharma
- Buyer based in
- Denmark
- Seller based in
- Japan
- Completed
- 18 Aug 2026
- Sector
- Pharma
- Tags
- Pharma, Dermatology, Rare Disease
Similar deals
- ANI Pharmaceuticals acquisition of Egetis 2026 · US$560m · Pharma
- SERB Pharmaceuticals acquisition of Exclusive development and commercialisation rights to Idefirix in Europe and MENA May 2026 · US$134m · Pharma
- Chiesi Group acquisition of KalVista Pharmaceuticals Apr 2026 · US$1.9bn · Pharma
- Neurocrine Biosciences acquisition of Soleno Therapeutics Apr 2026 · US$2.9bn · Biotech
- LEO Pharma acquisition of Replay May 2026 · US$50m · Biotech

